The Department of Defense's FY25 Amyotrophic Lateral Sclerosis Research Program (ALSRP) has announced the Therapeutic Development Award (TDA) to support innovative ALS research from preclinical validation to FDA Investigational New Drug studies. The program will allocate approximately $9.8 million for about four awards, each capped at $1.5 million and intended for a maximum three-year period. Application deadlines include a pre-application due by June 6, 2025, and a full application by August 27, 2025. Eligible applicants span both extramural and intramural organizations and should demonstrate proof-of-concept efficacy in preclinical models of ALS. Key goals include empirical therapeutic studies with a focus on biomarker development alongside therapeutic efforts. Non-clinical studies are encouraged, leveraging existing human specimen resources rather than recruiting new participants. Applications must highlight proposed strategies for collaboration, transition to clinical testing, and regulatory considerations, alongside comprehensive scientific and budget plans. The review process includes a dual-tier evaluation of technical merit and programmatic relevance, with final funding decisions reflecting the alignment with ALSRP objectives and available funding. This initiative illustrates a concerted effort to advance ALS treatment options significantly while aiming to benefit military Service Members, Veterans, and the general public.